{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:34:33Z","timestamp":1762623273094},"reference-count":51,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Expression of protein kinase CK2 is frequently deregulated in cancer and mounting evidence implicates CK2 in tumorigenesis. Here, we show that CK2 is overexpressed and hyperactivated in chronic lymphocytic leukemia (CLL). Inhibition of CK2 induces apoptosis of CLL cells without significantly affecting normal B and T lymphocytes. Importantly, this effect is not reversed by coculture with OP9 stromal cells, which are otherwise capable of rescuing CLL cells from in vitro spontaneous apoptosis. CLL cell death upon CK2 inhibition is mediated by inactivation of PKC, a PI3K downstream target, and correlates with increased PTEN activity, indicating that CK2 promotes CLL cell survival at least in part via PI3K-dependent signaling. Although CK2 antagonists induce significant apoptosis of CLL cells in all patient samples analyzed, sensitivity to CK2 blockade positively correlates with the percentage of CLL cells in the peripheral blood, \u03b22 microglobulin serum levels and clinical stage. These data suggest that subsets of patients with aggressive and advanced stage disease may especially benefit from therapeutic strategies targeting CK2 function. Overall, our study indicates that CK2 plays a critical role in CLL cell survival, laying the groundwork for the inclusion of CK2 inhibitors into future therapeutic strategies.<\/jats:p>","DOI":"10.1182\/blood-2010-04-277947","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T02:55:39Z","timestamp":1279767339000},"page":"2724-2731","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"116","author":[{"given":"Leila R.","family":"Martins","sequence":"first","affiliation":[{"name":"Cancer Biology Unit, Instituto de Medicina Molecular, Lisbon University Medical School, Lisbon, Portugal;"}]},{"given":"Paulo","family":"L\u00facio","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Doen\u00e7as Cr\u00f3nicas (CEDOC), Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa and Instituto Portugu\u00eas de Oncologia, Lisbon, Portugal; and"}]},{"given":"Milene C.","family":"Silva","sequence":"additional","affiliation":[{"name":"Cancer Biology Unit, Instituto de Medicina Molecular, Lisbon University Medical School, Lisbon, Portugal;"}]},{"given":"Kenna L.","family":"Anderes","sequence":"additional","affiliation":[{"name":"Cylene Pharmaceuticals, San Diego, CA"}]},{"given":"Paula","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Doen\u00e7as Cr\u00f3nicas (CEDOC), Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa and Instituto Portugu\u00eas de Oncologia, Lisbon, Portugal; and"}]},{"given":"Maria G.","family":"Silva","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Doen\u00e7as Cr\u00f3nicas (CEDOC), Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa and Instituto Portugu\u00eas de Oncologia, Lisbon, Portugal; and"}]},{"given":"Jo\u00e3o T.","family":"Barata","sequence":"additional","affiliation":[{"name":"Cancer Biology Unit, Instituto de Medicina Molecular, Lisbon University Medical School, Lisbon, Portugal;"}]}],"member":"234","reference":[{"issue":"1","key":"2019111802094504600_B1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia.","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111802094504600_B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","article-title":"B-cell chronic lymphocytic leukemia: a bird of a different feather.","volume":"17","author":"Caligaris-Cappio","year":"1999","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111802094504600_B3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ajh.20987","article-title":"Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.","volume":"82","author":"Weinberg","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111802094504600_B4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1096\/fj.02-0473rev","article-title":"One-thousand-and-one substrates of protein kinase CK2?","volume":"17","author":"Meggio","year":"2003","journal-title":"FASEB J"},{"issue":"11\u201312","key":"2019111802094504600_B5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00018-009-9150-2","article-title":"Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival.","volume":"66","author":"St-Denis","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2019111802094504600_B6","article-title":"Addiction to protein kinase CK2: a common denominator of diverse cancer cells?","author":"Ruzzene","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2019111802094504600_B7","first-page":"2262","article-title":"Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung.","volume":"54","author":"Daya-Makin","year":"1994","journal-title":"Cancer Res"},{"issue":"1","key":"2019111802094504600_B8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/bbrc.1994.1904","article-title":"Asymmetric expression of protein kinase CK2 subunits in human kidney tumors.","volume":"202","author":"Stalter","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2019111802094504600_B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/1097-0347(200007)22:4<341::AID-HED5>3.0.CO;2-3","article-title":"Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro.","volume":"22","author":"Faust","year":"2000","journal-title":"Head Neck"},{"issue":"1","key":"2019111802094504600_B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pros.2990240105","article-title":"Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate.","volume":"24","author":"Yenice","year":"1994","journal-title":"Prostate"},{"issue":"25","key":"2019111802094504600_B11","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/sj.onc.1204411","article-title":"Protein kinase CK2 in mammary gland tumorigenesis.","volume":"20","author":"Landesman-Bollag","year":"2001","journal-title":"Oncogene"},{"issue":"5","key":"2019111802094504600_B12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2005-11-013672","article-title":"Multiple myeloma cell survival relies on high activity of protein kinase CK2.","volume":"108","author":"Piazza","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111802094504600_B13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-06-1602","article-title":"Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111802094504600_B14","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability.","volume":"118","author":"Silva","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111802094504600_B15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/sj.leu.2404831","article-title":"Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.","volume":"21","author":"Rodriguez","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111802094504600_B16","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111802094504600_B17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/10428190410001683642","article-title":"PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.","volume":"45","author":"Plate","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111802094504600_B18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","article-title":"A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.","volume":"18","author":"Cuni","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"2019111802094504600_B19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation.","volume":"276","author":"Torres","year":"2001","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111802094504600_B20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"5175","key":"2019111802094504600_B21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.8066449","article-title":"Generation of lymphohematopoietic cells from embryonic stem cells in culture.","volume":"265","author":"Nakano","year":"1994","journal-title":"Science"},{"issue":"2","key":"2019111802094504600_B22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk Res"},{"issue":"1","key":"2019111802094504600_B23","first-page":"23","article-title":"The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.","volume":"73","author":"Melo","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"2019111802094504600_B24","article-title":"Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.","author":"Silva","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"2019111802094504600_B25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cyto.b.20132","article-title":"Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.","volume":"70","author":"Letestu","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"2019111802094504600_B26","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111802094504600_B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia.","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"issue":"11\u201312","key":"2019111802094504600_B28","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00018-009-9155-x","article-title":"Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.","volume":"66","author":"Battistutta","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2019111802094504600_B29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00262-005-0675-4","article-title":"T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil.","volume":"55","author":"Mellstedt","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2019111802094504600_B30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2796.2008.02030.x","article-title":"Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.","volume":"264","author":"Ghia","year":"2008","journal-title":"J Intern Med"},{"issue":"5","key":"2019111802094504600_B31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2019111802094504600_B32","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/MCB.20.14.5010-5018.2000","article-title":"Phosphorylation of the PTEN tail regulates protein stability and function.","volume":"20","author":"Vazquez","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2019111802094504600_B33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1073\/pnas.0812473106","article-title":"Phosphorylation keeps PTEN phosphatase closed for business.","volume":"106","author":"Ross","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5385","key":"2019111802094504600_B34","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1126\/science.281.5385.2042","article-title":"Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1.","volume":"281","author":"Le Good","year":"1998","journal-title":"Science"},{"issue":"3","key":"2019111802094504600_B35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.leu.2404113","article-title":"Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.","volume":"20","author":"Ringshausen","year":"2006","journal-title":"Leukemia"},{"issue":"37","key":"2019111802094504600_B36","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/onc.2009.179","article-title":"The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.","volume":"28","author":"Baudot","year":"2009","journal-title":"Oncogene"},{"issue":"12","key":"2019111802094504600_B37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111802094504600_B38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0960-9822(95)00277-6","article-title":"Protein kinase C is regulated in vivo by three functionally distinct phosphorylations.","volume":"5","author":"Keranen","year":"1995","journal-title":"Curr Biol"},{"issue":"2","key":"2019111802094504600_B39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.21554","article-title":"A retrospective comparison of three sequential groups of patients with Recurrent\/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.","volume":"106","author":"Wierda","year":"2006","journal-title":"Cancer"},{"issue":"9617","key":"2019111802094504600_B40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia.","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"issue":"30","key":"2019111802094504600_B41","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1074\/jbc.273.30.19183","article-title":"Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5.","volume":"273","author":"Raman","year":"1998","journal-title":"J Biol Chem"},{"issue":"8","key":"2019111802094504600_B42","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V99.8.2969","article-title":"Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.","volume":"99","author":"Barragan","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111802094504600_B43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"issue":"15","key":"2019111802094504600_B44","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2009-08-239483","article-title":"CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111802094504600_B45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"issue":"1\u20133","key":"2019111802094504600_B46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-5793(02)03274-X","article-title":"Direct identification of PTEN phosphorylation sites.","volume":"528","author":"Miller","year":"2002","journal-title":"FEBS Lett"},{"key":"2019111802094504600_B47","first-page":"135","article-title":"Differential effects on CLL cell survival exerted by different microenvironmental elements.","volume":"294","author":"Ghia","year":"2005","journal-title":"Curr Top Microbiol Immunol"},{"issue":"13","key":"2019111802094504600_B48","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111802094504600_B49","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2007-08-108605","article-title":"CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.","volume":"111","author":"Patten","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111802094504600_B50","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2009-09-242719","article-title":"Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.","volume":"115","author":"Ghosh","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111802094504600_B51","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/15\/2724\/1329980\/zh804110002724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/15\/2724\/1329980\/zh804110002724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:10:06Z","timestamp":1574061006000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/15\/2724\/27660\/Targeting-CK2-overexpression-and-hyperactivation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,14]]},"references-count":51,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2010,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-04-277947","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,14]]}}}